BOCA RATON, Fla., June 05, 2017 (GLOBE NEWSWIRE) — Sensus Healthcare, Inc. (Nasdaq:SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids, with superficial radiation therapy (SRT), today announced Joe Sardano, the Company’s Chief Executive Officer, will present a corporate overview to investors at the 2017 Marcum MicroCap Conference on Thursday, June 15th at 11:00 a.m. Eastern time. The conference will be held at the Grand Hyatt Hotel in New York City on June 15th and 16th.
Mr. Sardano’s presentation will be webcast live on the internet and can be accessed by visiting the Investor Relations section of the Company’s website at www.sensushealthcare.com. A replay of the webcast will be archived on Sensus Healthcare’s website for 90 days following the presentation.
The Marcum MicroCap Conference (www.marcummicrocap.com) is a nationally recognized forum for publicly traded companies with less than $500 million in market capitalization to network with fund managers and high net worth investors who focus on small cap equities. More than 2000 investors and other participants from every segment of the microcap marketplace attend each year, including venture and lower middle-market private equity investors, institutional investors, directors, investment bankers, and buy- and sell-side analysts, as well as senior executive teams from presenting companies and service providers to the microcap marketplace.
The conference is presented by Marcum LLP, a top national accounting and advisory firm registered with the Public Company Accounting Oversight Board (PCAOB). Marcum’s Assurance Division provides the most up-to-date service and guidance on SEC accounting and reporting issues. Services include Financial Statement Audits in accordance with PCAOB standards; Tax Compliance and Advisory Services; Due Diligence; Agreed-Upon Procedures and Other Attest Work; Internal Audit Services; Sarbanes-Oxley Section 404 Compliance Services and Software; Technical Accounting Assistance; and IPO Assistance. For more information, visit www.marcumllp.com.
About Sensus Healthcare
Sensus Healthcare, Inc. (NASDAQ:SRTS) is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy X-ray radiation technology known as superficial radition therapy (SRT), which is a result of over a decade of dedicated research and development activities. Sensus has successfully incorporated the SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, the SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For further information, please visit http://www.sensushealthcare.com.
LHA Investor Relations
Kim Sutton Golodetz